Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SHR-A1811 + bevacizumab
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
SHR-A1811 + bevacizumab is a combination therapy under investigation for the treatment of HER2-positive breast cancer, including cases with brain metastases. SHR-A1811 is a third-generation antibody-drug conjugate (ADC) composed of an anti-HER2 antibody (trastuzumab), a cleavable linker, and a topoisomerase I inhibitor payload. It targets HER2-expressing or mutated tumors by delivering cytotoxic agents directly to cancer cells, resulting in cell death[5][7]. Bevacizumab is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and reducing tumor blood supply[8]. The combination aims to enhance antitumor efficacy by simultaneously targeting tumor cells and their supporting vasculature. This regimen has shown promising activity in early-phase clinical trials for advanced breast cancer with brain metastasis[3].
- Brand names
- Avastin
02
Targets
TOP1 (DNA Topoisomerase I)VEGFA (Vascular endothelial growth factor A)ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on SHR-A1811 + bevacizumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SHR-A1811 + bevacizumab.